Early Translational II
$1 752 058
Many neurological disorders are characterized by an imbalance between excitation and inhibition. Our ultimate goal: to develop a cell-based therapy to modulate aberrant brain activity in the treatment of these disorders. Our initial focus is on epilepsy. In 20-30% of these patients, seizures are unresponsive to drugs, requiring invasive surgical resection of brain regions with aberrant activity. The candidate cells we propose to develop can inhibit hyperactive neural circuits after implantation into the damaged brain. As such, these cells could provide an effective treatment not just for epilepsy, but also for a variety of other neurological conditions like Parkinson's, traumatic brain injury, and spasticity after spinal cord injury. We propose to bring a development candidate, a neuronal cell therapy, to the point of preclinical development. The neurons that normally inhibit brain circuits originate from a region of the developing brain called the medial ganglionic eminence (MGE). When MGE cells are grafted into the postnatal or adult brain, they disperse seamlessly and form inhibitory neurons that modulate local circuits. This property of MGE cells has not been shown for any other type of neural precursor. Our recent studies demonstrate that MGE cells grafted into an animal model of epilepsy can significantly decrease the number and severity of seizures. Other "proof-of-principle" studies suggest that these progenitor cells can be effective treatments in Parkinson's. In a separate effort, we are developing methods to differentiate large numbers of human MGE (H-MGE) cells from embryonic stem (ES) cells. To translate this therapy to humans, we need to determine how many MGE cells are required to increase inhibition after grafting and establish that this transplantation does not have unwanted side-effects. In addition, we need simple assays and reagents to test preparations of H-MGE cells to determine that they have the desired migratory properties and differentiate into nerve cells with the expected inhibitory properties. At present, these issues hinder development of this cell-based therapy in California and worldwide. We propose: (1) to perform "dose-response" experiments using different graft sizes of MGE cells and determine the minimal amount needed to increase inhibition; (2) to test whether MGE transplantation affects the survival of host neurons or has unexpected side-effects on the behavior of the grafted animals; (3) to develop simple in vitro assays (and identify reagents) to test H-MGE cells before transplantation. Our application takes advantage of an established multi-lab collaboration between basic scientists and clinicians. We also have the advice of neurosurgeons, epilepsy neurologists and a laboratory with expertise in animal behavior. If a safe cell-based therapy to replace lost inhibitory interneurons can be developed and validated, then clinical trials in patients destined for invasive neurosurgical resections could proceed.
Statement of Benefit to California:
This proposal is designed to accelerate progress toward development of a novel cell-based therapy with potentially broad benefit for the treatment of multiple neurological diseases. The potential to translate our basic science findings into a treatment that could benefit patients is our primary focus and our initial target disease is epilepsy. This work will provide benefits to the State of California in the following areas: * California epilepsy patients and patients with other neurological diseases will benefit from improved therapies. The number of patients refractory to available medications is significant: a recent report from the Center for Disease Control and Prevention [ http://www.cdc.gov/epilepsy/ ] estimates that 1 out of 100 adults have epilepsy and up to one-third of these patients are not receiving adequate treatment. In California, it is one of the most common disabling neurological conditions. In most states, including California, epileptic patients whose seizures aren't well-controlled cannot obtain a driver's license or work certain jobs -- truck driving, air traffic control, firefighting, law enforcement, and piloting. The annual cost estimates to treat epilepsy range from $12 to $16 billion in the U.S. Current therapies curb seizures through pharmacological management but are not designed to modify brain circuits that are damaged or dysfunctional. The goals of our research program is to develop a novel cell-based therapy with the potential to eliminate seizures and improve the quality of life for this patient population, as well as decrease the financial burden to the patients' families, private insurers, and state agencies. Since MGE cells can mediate inhibition in other neurological and psychiatric diseases, the neural based therapy we are proposing is likely to have a therapeutic and financial impact that is much broader. * Technology transfer in California. Historically, California institutions have developed and implemented a steady flow of technology transfer. Based on these precedents and the translational potential of our research goals, both to provide bioassays and potentially useful markers to follow the differentiation of MGE cells, this program is likely to result in licensing of further technology to the corporate sector. This will have an impact on the overall competitiveness of our state's technology sector and the resulting potential for creation of new jobs. * Stem cell scientists training and recruitment in California. As part of this proposal we will train a student, technicians, and associated postdocs in MGE progenitor derivation, transplantation, and cell-based therapy for brain repair. Moreover, the translational nature of the disease-oriented proposal will result in new technology which we expect to be transferable to industry partners for facilitate development into new clinical alternatives.
This application for a Development Candidate Feasibility Award focuses on a human embryonic stem cell (hESC)-derived cell therapy for refractory epilepsy. The applicant presents published and preliminary data supporting the ability of inhibitory cells from a region of the developing brain called the medial ganglionic eminence (MGE) to inhibit hyperactive neural circuits in animal models of epilepsy. The applicant proposes to move this work toward clinical translation in three Specific Aims: (1) to determine the effect of transplanted MGE cell number on the migration, integration and function of these cells; (2) to examine potential side effects of MGE cell transplantation; and (3) to identify and validate biomarkers for stages of hESC differentiation into MGE cells and their subsequent maturation. Reviewers found the scientific rationale for this proposal to be quite strong. They noted that the transplantation of inhibitory neurons to treat diseases of hyperactive neural circuits is logical and clever. Refractory epilepsy represents a significant unmet medical need, so this approach could have a major impact. Reviewers agreed that transplanted MGE cells have the potential to treat other conditions as well, including Parkinson’s disease, traumatic brain injury and spasticity following spinal cord injury. They appreciated that important translational issues are addressed in the proposal, including the question of appropriate cell number and stage of cell maturation, and to what extent transplanted cells integrate and affect endogenous neural circuits. Reviewers noted that there is a significant amount of work proposed with rodent cells, but agreed that it would provide valuable comparative data for the human cell studies. The reviewers described the research plan as intense but feasible. They were impressed by the preliminary data presented, which is extremely supportive of the proposal’s rationale and feasibility. In particular, reviewers appreciated the preliminary data describing transplanted cell apoptosis and electrophysiological dose response. They found the aims logical and likely to yield interesting data that will benefit the field. Reviewers also appreciated the thorough discussion of caveats and potential pitfalls. They did note that data confirming the benefits of hESC-derived MGE cells in rodent epilepsy models would be helpful, as arborization of human MGE neurons is likely more extensive than that of rodent neurons, which could have behavioral consequences. Reviewers also would have appreciated more detail about the behavioral analyses proposed in Aim 2. Finally, they suggested that the applicant place a greater emphasis on the identification and purification of specific interneuron subtypes (e.g. parvalbumin positive) as the work moves from rodent into human cells. Reviewers described the principal investigator (PI) and research team as world-class. The PI is well established and highly qualified and has formed collaborations with other distinguished investigators. Reviewers appreciated that these collaborators contribute expertise in electrophysiology, epilepsy and hESC differentiation, complementing the PI’s considerable expertise in neural stem cell biology. They found the resources and environment to be outstanding and described the research team as ideally suited to carry out the proposed research. Overall, the reviewers were highly enthusiastic about this proposal. They praised the outstanding research team and impressive preliminary data. Reviewers felt strongly that this proposal could have a significant impact not only on the treatment of refractory epilepsy, but also a number of other neurological diseases.